Cargando…

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

BACKGROUND: Irritable bowel syndrome is classified as a functional gastrointestinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel movement disorder. It affects up to 15% of the world’s population. Among its subtypes, the most common is diarrhoea predomina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Kamesh, Ghuman, Harparam Singh, Handa, Shivani Vijay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Short Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582649/ https://www.ncbi.nlm.nih.gov/pubmed/28894393 http://dx.doi.org/10.1177/1179552217728905

Ejemplares similares

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome
por: Shankar, Vijay, et al.
Publicado: (2015)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
por: DuPont, Herbert L., et al.
Publicado: (2016)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
por: Liu, Zuojing, et al.
Publicado: (2022)

Case Report: Migrainous Infarct without Aura
por: Gupta, Kamesh, et al.
Publicado: (2017)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

Innate Immune Memory: The Latest Frontier of Adjuvanticity
por: Töpfer, Elfi, et al.
Publicado: (2015)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

3185 A Randomized Controlled Trial Comparing the Nonabsorbable Antibiotic Rifaximin vs. Dietary Intervention Low in Fermentable Sugars (FODMAP) in Irritable Bowel Syndrome
por: Lee, Allen, et al.
Publicado: (2019)

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
por: Cash, Brooks D., et al.
Publicado: (2017)

Molecular imaging in radiology: the latest fad or the new frontier?
por: Krestin, Gabriel P., et al.
Publicado: (2006)

Epigenetic Mechanisms in Irritable Bowel Syndrome
por: Mahurkar-Joshi, Swapna, et al.
Publicado: (2020)

Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
por: Cui, Xiufang, et al.
Publicado: (2021)

Parasites in Mexican patients with irritable bowel syndrome: a case-control study
por: Ramirez-Miranda, Maria Elena, et al.
Publicado: (2010)

GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome
por: Bonfiglio, Ferdinando, et al.
Publicado: (2021)

Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α
por: Deltenre, Pierre, et al.
Publicado: (2021)

Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients
por: Nagel, Robyn, et al.
Publicado: (2016)

Cytokine Profile and Immunoglobulin E-mediated Serological Food Hypersensitivity in Patients With Irritable Bowel Syndrome With Diarrhea
por: Katsumata, Ryo, et al.
Publicado: (2018)

Mechanism-Oriented Therapy of Irritable Bowel Syndrome
por: Malagelada, Juan R., et al.
Publicado: (2016)

Lack of Association between Interleukin 12 C(-1188)A Polymorphism and Irritable Bowel Syndrome
por: Barkhordari, Elham, et al.
Publicado: (2011)

Latest developments on the mechanism of action of membrane disrupting peptides
por: Pandidan, Sara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_611fsb2nnk2q35bk0376mtu6db